Methylergonovine maleate is a semisynthetic ergot alkaloid derivative that exerts its primary therapeutic effects by promoting smooth muscle contractions, particularly in the uterus. The drug's method of action in activating smooth muscle contractions comprises many routes, including interactions with different receptors and direct effects on smooth muscle cells.
It is a kind of serotonin receptor agonism. Smooth muscle cells have serotonin receptors of the 5-HT2A and 5-HT2B subtypes. That compound produces potent agonists. The product binds to these receptors. At that time, it initiates a complicated signaling cascade that eventually causes a rise in intracellular calcium levels.
We could make further steps. It can increase intracellular calcium. The compound promotes the formation of inositol triphosphate (IP3). Activating serotonin receptors is one of the methods. So, calcium is released from intracellular reserves. It includes the sarcoplasmic reticulum. Voltage-gated calcium channels can facilitate the extracellular calcium's entry into the smooth muscle cells.
It promotes calcium-mediated smooth muscle contraction. A calcium-calmodulin complex is formed when the protein calmodulin binds to the increased intracellular calcium levels brought about by methylergonovine's activities. Following that, this combination triggers myosin light chain kinase (MLCK). It is an enzyme that phosphorylates myosin's regulatory light chains.
It helps actin-myosin cross-bridge formation. The phosphorylation of myosin light chains by MLCK allows for the formation of actin-myosin cross-bridges, which are the fundamental units of muscle contraction. These cross-bridges cyclically attach, pull, and detach from the actin filaments, generating force and causing the smooth muscle fibers to shorten and contract.
Its effects mediated by serotonin receptors are essential to be talked. The product also exhibits direct actions on smooth muscle cells that contribute to its uterotonic activity. The compound can directly depolarize smooth muscle cell membranes. The compound leads to the opening of voltage-gated calcium channels and an influx of calcium ions. This mechanism is independent of the drug's serotonergic effects and further enhances the contractile response of smooth muscle cells.
How Does Methylergonovine Specifically Affect Uterine Smooth Muscle?
Methylergonovine primarily prevents and treats postpartum hemorrhage by promoting smooth muscle contractions in different tissues, especially in uterine smooth muscle.
It helps uterine smooth muscle contraction. During pregnancy, the uterine smooth muscle undergoes significant hypertrophy and hyperplasia in preparation for labor and delivery. The product acts on the uterine smooth muscle cells, promoting strong and coordinated contractions through the mechanisms described above.
It is good for the compression of blood vessels. During pregnancy, the uterus experiences blood vessel dilation to support fetal development. The compound induces uterine contractions and constricts these vessels. Then, it reduces blood flow and aids in postpartum bleeding control.
Helping with the synergistic effects of oxytocin is another advantage. The product and oxytocin, both uterotonic agents, can work together to enhance uterine contractions. Oxytocin targets the upper part of the uterus. The product has a stronger impact on the lower segment. It results in a synchronized and effective contraction of the entire uterus.
It also aids prolonged uterine tone. In addition to promoting strong contractions, the compound also helps maintain uterine tone, which is essential for preventing postpartum hemorrhage. By sustaining uterine smooth muscle contractions for an extended period, the product helps the uterus remain tightly contracted and prevents excessive bleeding.
What Are the Clinical Applications of Methylergonovine's Effects on Smooth Muscle?
Methylergonovine is mainly used in obstetrics to treat postpartum hemorrhage. Its capacity to induce smooth muscle contractions has also expanded its application to various other medical fields.
One of the applications is the treatment of postpartum hemorrhage. Our product is the most frequently injected, either intramuscularly or intravenously, afterward the dropping placenta. The aim is to have blood-shed-controlling uterine contractiles. Furthermore, it can also be used for the treatment of postpartum hemorrhage that is projected to occur, such as people with a history of postpartum hemorrhage or uterine can be treated with it.
It helps the management of uterine bleeding. The product is sometimes utilized off-label for the management of atypical uterine bleeding unrelated to pregnancy. This may include addressing conditions such as menorrhagia (excessive menstrual bleeding) or bleeding associated with uterine fibroids or endometrial polyps.
Another one is its migraine treatment. The compound has been explored as an unsuccessful therapy for migraine headaches because of its vasoconstrictive characteristics. By constricting cranial blood vessels, the drug can help relieve migraine pain and associated symptoms.
Gastrointestinal bleeding is also another application. The product is used off-label to treat gastrointestinal bleeding because of its capacity to constrict blood vessels and encourage smooth muscle contractions. The medication can help decrease bleeding from causes including peptic ulcers or gastrointestinal cancers by decreasing blood flow to the afflicted region.
It is potentially used in other conditions. Studies have looked at the possible use of the product for treating additional disorders involving malfunctioning smooth muscles, including pulmonary hypertension in some types, irritable bowel syndrome, and urine incontinence. However the safety and effectiveness of the medication in these contexts are still being investigated, so these uses are not entirely proven.
Despite its ability to stimulate smooth muscle contractions, caution should be taken with methylergonovine for its vasoconstrictive properties. So, it is crucial to have a qualified healthcare provider oversee the prescription. The administration of this medication carefully evaluates the balance of benefits and risks for each patient.
References:
1. Methylergonovine Maleate. In: Lexi-Drugs Online [Internet]. Hudson (OH): Lexicomp Inc.; [updated 2023 Mar 13; cited 2023 Mar 21]. Available from: https://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6642
2. Methylergonovine Maleate. In: IBM Micromedex [Internet]. Greenwood Village (CO): IBM Corporation; [updated 2023 Mar 10; cited 2023 Mar 21]. Available from: https://www.micromedexsolutions.com
3. Bouwmeester FW, Bolte AC, van Geijn HP. Pharmacological and cardiovascular effects of methylergometrine and methylergonovine in women with hypertensive disease in pregnancy. Eur J Obstet Gynecol Reprod Biol. 1988;29(1):51-62.
4. Derry S, Sven-Åke R, Moore RA. Methylergonovine maleate in the prevention and treatment of post-partum hemorrhage: a review. J Obstet Gynaecol. 2005;25(8):751-757.
5. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2015.
6. Methylergonovine Maleate. In: DrugBank Online [Internet]. Edmonton (AB): University of Alberta; [updated 2023 Feb 13; cited 2023 Mar 21]. Available from: https://go.drugbank.com/drugs/DB00847
7. Shaughn Bryant, Anita Ravishankar, and Kenneth Steier. Methylergonovine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; [updated 2022 Aug 8; cited 2023 Mar 21]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560761/
8. Sanborn BM. Relationship of ion channel activity to control of myometrial calcium. J Soc Gynecol Investig. 2000;7(1):4-11.
9. Shojo H, Kaneko Y. Oxytocin-induced phosphorylation of myosin light chain is mediated by extracellular calcium influx in the myometrium of pregnant rats. J Smooth Muscle Res. 2001;37(2):35-50.